ReviewThe AAPS journal2026
HLA Class II Alleles DRB1*11:01 and DQB1*03:01 Unmask Immunogenetic Susceptibility to Anti-Nivolumab Antibodies in Combination with Ipilimumab.
Review in The AAPS journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Biologic combinations that modulate immune responses are increasingly used in oncology, enhancing anti-tumor immunity but also raising the risk of anti-drug antibody (ADA) development. Nivolumab administered in combination with ipilimumab results in significantly higher nivolumab ADA incidence (44%) compared to nivolumab monotherapy (12%). While previous analyses showed no clinical impact of nivolumab ADA on safety and efficacy for the combination, it provided a unique dataset to evaluate genetic predispositions to nivolumab ADA development and impact of co-administered ipilimumab. HLA Class II alleles were evaluated for associations with nivolumab ADA. Logistic regression analyses were performed on HLA-DRB1, DQB1, and DQA1 alleles from melanoma subjects treated with nivolumab plus ipilimumab and nivolumab alone. Univariate screening identified candidate alleles that were associated with immunogenicity. This was followed by multivariable modeling to assess independent and combined effects after accounting for sex, age and region. Multivariable analyses indicated that DRB1*11:01 (Odds Ratio (OR) = 2.5, p-value (p) = 0.011) and DQB1*03:01 (OR = 3.2, p = 0.0002) were each significantly associated with nivolumab ADA positivity in combination therapy. The combined presence of both alleles conferred an even stronger association (OR = 4.1, p = 0.0017). No significant associations were observed for nivolumab monotherapy. In silico predictions and MHC-associated peptide proteomics (MAPPs) confirmed high-affinity binding of a nivolumab framework peptide (a known Treg epitope) to DRB1*11:01. DRB1*11:01 and DQB1*03:01 may predict anti-nivolumab antibody development in the context of combination therapy. These findings underscore the role of host genetics and immune modulation by ipilimumab in shaping immunogenicity.
Indexed as
Identifiers
42162441What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.